United States Vacuum Blood Collection Tube Market Size, Share, Growth, and Industry Analysis, By Product Type (Serum Tubes, Plasma Separation Tubes, Heparin Tubes, EDTA Tubes), By Material (Plastic, Glass) and Forecast, 2026-2034

United States Vacuum Blood Collection Tube Market Trends

Shift Toward Plastic, Closed Collection and Workflow-Compatible Tubes

Technology development increasingly centers on PET-based plastic tubes, standardized draw volumes, separator gels, clot activators and closures compatible with automated laboratory workflows. FDA documentation for BD serum separator tubes identifies 3.5–10 mL draw volumes, 3 principal tube dimensions, a minimum 30-minute clotting period and recommended centrifugation at 1,100–1,300 RCF for 10–15 minutes.

Closed specimen collection is also emphasizing preanalytical quality. BD reports that up to 70% of clinical decisions rely on laboratory-test information and that incorrect tube fill volume accounts for 10–20% of specimen rejection cases. Its referenced laboratory-professional evaluation included 225 respondents. These factors support demand for controlled-vacuum filling, safety closures, automation compatibility and standardized additive-to-blood ratios.

United States Vacuum Blood Collection Tube Market Drivers

High Diagnostic Testing Intensity and Standardized Specimen Collection

Clinical laboratories require consistent specimens across chemistry, hematology, coagulation, glucose and infectious-disease workflows. Laboratory results influence up to 70% of clinical decisions, while approximately 12 million U.S. adults are affected annually by outpatient diagnostic errors, reinforcing emphasis on specimen integrity. Incorrect filling contributes to 10–20% of specimen rejection, creating operational incentives for controlled-vacuum collection and standardized tube configurations.

United States Vacuum Blood Collection Tube Market Restraints

Preanalytical Errors and Supply-Chain Dependence

Tube performance depends on fill volume, additive ratios, closure integrity, centrifugation and handling. Serum separator products may require at least 30 minutes of clotting and 10–15 minutes of centrifugation at 1,100–1,300 RCF, adding process sensitivity. FDA-related supply disruptions in adjacent blood-culture consumables during 2024 also demonstrated vulnerability to component shortages, including transitions between plastic and glass supply.

United States Vacuum Blood Collection Tube Market Opportunities

Expansion of Safer and Lower-Volume Specimen Collection

Lower-volume and capillary systems can broaden collection options while reducing workflow complexity. In April 2026, FDA granted substantial-equivalence clearance to the BD MiniDraw capillary system incorporating an SST capillary collection tube; the submission was received on July 30, 2025, with the decision issued on April 10, 2026. Continued development around automated processing, separator technologies and closed transfer systems creates opportunities across hospitals, laboratories and outpatient settings.

Challenges in United States Vacuum Blood Collection Tube Market

Balancing Sample Quality, Compatibility and Cost

Manufacturers must maintain vacuum accuracy, additive stability, closure performance and analyzer compatibility across multiple tube formats. BD SST products span 3.5–10 mL draw volumes and 3 primary dimensions, while collection protocols can require 5 inversions, at least 30 minutes of clotting and up to 15 minutes of centrifugation. Managing these variables while reducing the 10–20% rejection exposure associated with incorrect fill volumes remains a significant laboratory challenge.

United States Vacuum Blood Collection Tube Market Segmentation

The market is segmented by product type, material, application, end user and distribution channel. In the supplied 2026 dataset, serum tubes account for approximately 34.0% of product revenue and plastic for approximately 59.1% of material revenue.

By Product Type

Serum tubes lead at USD 250.02 million in 2026, rising from USD 241.59 million in 2025 to USD 328.98 million by 2034, at a 3.49% CAGR. Their 2026 contribution is approximately 34.0%.

Others—including thrombin and trace-element tubes—record the fastest supplied product CAGR at 3.54%, increasing from USD 38.29 million in 2026 to USD 50.58 million in 2034. Plasma separation tubes reach USD 173.70 million, heparin USD 132.21 million, EDTA USD 100.10 million, ESR USD 91.20 million and glucose tubes USD 83.00 million by 2034.

By Material

Plastic leads at USD 434.71 million in 2026, approximately 59.1% of the supplied material total, and is forecast at USD 568.47 million in 2034, registering a 3.41% CAGR.

Glass accounts for USD 300.43 million in 2026 and reaches USD 389.83 million by 2034, at 3.31% CAGR. Plastic therefore remains both the larger and faster-growing material category in the supplied dataset.

By Application

The application structure comprises routine chemistry, blood sugar testing, coagulation testing, lipid profile, infectious-disease testing and other procedures. These applications collectively operate across 6 defined categories and use serum, plasma, EDTA, heparin and glucose-specific collection formats.

Application-level revenue, percentage contribution and CAGR were not supplied. Consequently, no unsupported largest-subsegment value or fastest-growing application CAGR is introduced.

By End User

The end-user framework contains 5 categories: hospitals, diagnostic laboratories, blood banks, ambulatory surgical centers, and academic/research institutions. Demand is linked to routine diagnostics, emergency testing, outpatient collections and specialized research workflows.

End-user revenue, percentage shares and CAGRs were not supplied, preventing statistically valid identification of a largest or fastest-growing end-user category.

By Distribution Channel

Distribution covers 4 channels: direct tender, retail sales, online sales and distributors. Institutional procurement commonly requires high-volume standardized supplies, while retail, distributor and digital channels address decentralized purchasing requirements.

Channel-specific 2025, 2026 and 2034 revenues and CAGRs were not provided; therefore no fabricated channel dominance or forecast is presented.

United States Vacuum Blood Collection Tube Market Counties Outlook

The U.S. can be evaluated operationally across the Northeast, Midwest, South and West; however, the mandatory dataset provides 0 county-level values, 0 state-level market shares and 0 regional CAGRs. Accordingly, the national 2026 value of USD 735.28 million and 2034 value of USD 959.77 million cannot be apportioned geographically without introducing unsupported assumptions.

At national level, product demand is led by serum tubes at approximately 34.0%, while plastic represents approximately 59.1% of material revenue in 2026. County production volumes, regional sector splits and individual state contributions are not available in the supplied tables and are therefore intentionally left unquantified.

Top players in United States Vacuum Blood Collection Tube Market

• Becton, Dickinson and Company
• Greiner Bio-One International GmbH
• Terumo Corporation
• Cardinal Health
• Sekisui Medical Co., Ltd.
• Sarstedt AG & Co. KG
• FL Medical S.r.l.
• Improve Medical Instruments Co., Ltd.
• Guangzhou Improve Medical Instruments Co., Ltd.
• Medtronic
• McKesson Corporation
• AdvaCare Pharma

Top Two Companies

• Becton, Dickinson and Company
• BD holds a prominent U.S. specimen-management position through the Vacutainer portfolio spanning serum, plasma, EDTA, heparin and specialty collection formats. FDA clearance activity continued in2026, including decisions datedApril 10, 2026for MiniDraw SST and Safety-Lok products. An exact company percentage share is not contained in the mandatory dataset and is therefore not estimated.
• Greiner Bio-One International GmbH

Greiner Bio-One competes through its VACUETTE portfolio, including serum, heparin, EDTA and separator configurations. FDA records identify VACUETTE lithium-heparin/gel and clot-activator/gel tube registrations under blood-collection classification862.1675. No defensible company-specific percentage share was supplied, so a numerical competitive share is not fabricated.

Recent Developments in United States Vacuum Blood Collection Tube Market

• 2026:FDA granted substantial-equivalence clearance onApril 10, 2026for the BD MiniDraw Capillary Blood Collection System with SST capillary tube.
• 2026:FDA granted clearance onApril 10, 2026for BD Vacutainer Safety-Lok Blood Collection Sets, including the pre-attached-holder configuration.
• 2026:BD launched its three-tube Vacutainer Urine Complete Cup Kit in the United States onFebruary 23, 2026, expanding closed specimen-management capabilities.
• 2025:Magnolia Medical Technologies received FDA clearance for Steripath Flow onSeptember 25, 2025, following a submission dated June 12, 2025.
• 2025:Venocare received FDA clearance for3Navi needle-free blood-collection-device configurations onMay 23, 2025, following its December 31, 2024 submission.

Research Methodology

United States Vacuum Blood Collection Tube Market Insights are developed using the supplied 2025, 2026 and 2034 quantitative tables as the controlling source for market valuation, segment contribution and CAGR. Percentage shares are calculated directly from supplied totals; for example, serum tubes represent approximately 34.0% of 2026 product revenue and plastic approximately 59.1% of material revenue. Regulatory and product-development statements are cross-checked against FDA and manufacturer sources. No missing application, end-user, distribution, regional or company-share values are extrapolated where numerical inputs were unavailable.